Immuno-Cell Int. Company Profile

10:25 EST 11th December 2018 | BioPortfolio

Immuno-Cell International © is specialized in the production of printed diagnostic slides and plates, for use in various types of diagnostic test kits. For the Diagnostic Industry (the manufactures of diagnostic test kits) we mostly manufacture these slides and cards custom-made (O.E.M. product). In addition we offer a wide range of standard items, which are available with low minimum order requirements. We supply our slides and cards to the leading test kits manufacturers. The secret of our success is due not only to our high quality product and the service that we povide, but also to the fact that we offer the most complete range of products in the field of diagnostic slides and cards


Hanswijk Ind.Park Motstraat 72/8


Phone: 32-15-43.31.88
Fax: 32-15-43.11.21

News Articles [1492 Associated News Articles listed on BioPortfolio]

Immunometabolism startup raises $30 million with help from GSK

Sitryx, a new biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, has closed its Series A financing ro...

Genentech, Affimed Launch Up-to-$5B Cancer Immunotherapy Collaboration

Genentech, a member of the Roche Group, has committed up to $5 billion in potential milestone payments and royalties to Affimed under a collaboration designed to develop and commercialize novel NK cel...

Immuno-Oncology Conference 2018

26 - 27 September, London, UK. Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key...

Mastering the Competitive World of Immuno-oncology

In recent years the oncology world has focused on using the immune system to target cancer, with CAR-T cell therapy and other success stories revolutionizing the field. Ulf Grawunder, CEO and founder ...

10 Top Immuno-Oncology Companies

One of the most highly anticipated methods to fight cancer is the immuno-oncology (I/O) sector. For investors interested in the field the Investing News Network (INN) has put together a list of top im...

RXi Pharmaceuticals and Karolinska Institutet Collaborate to Advance Immuno-Oncology Therapeutics

NewsThis collaboration will explore RXi's sd-rxRNA compounds against targets involved in T cell and NK cell differentiation.

SQZ Biotech signs up to $1bn immuno-oncology deal with Roche

Cell therapy company SQZ Biotechnologies has expanded its deal worth up to $1bn with Roche for the development and commercialisation...Read More... The post SQZ Biotech signs up to $1bn immuno-oncolog...

'Transformational' Results in Squamous Cell Lung Cancer

An immuno-chemotherapy combination again moves the bar forward in a difficult-to-treat subset of squamous cell lung cancer patients. Medscape Medical News

Drugs and Medications [19 Associated Drugs and Medications listed on BioPortfolio]

Sun care [Zenith Medicosm SL]

Drug Facts

Sun care [Zenith Medicosm SL]

Drug Facts

Alimta [Eli Lilly and Company]

These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA. ALIMTA (pemetrexed for injection) Lyophilized Powder, for ...

Hycamtin [GlaxoSmithKline LLC]

These highlights do not include all the information needed to use HYCAMTIN safely and effectively. See full prescribing information for HYCAMTIN. HYCAMTIN (topotecan) CapsulesInitial U.S. Approval: 19...

Patanol [Physicians Total Care, Inc.]

PubMed Articles [2627 Associated PubMed Articles listed on BioPortfolio]

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

The unprecedented success of immuno-oncology (I-O) agents targeting the cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/programmed death-ligand 1 pathways has stimulated the rapid...

A microfluidic competitive immuno-aggregation assay for high sensitivity cell secretome detection.

We report a high-sensitivity cell secretome detection method using competitive immuno-aggregation and a micro-Coulter counter. A target cell secretome protein competes with anti-biotin-coated micropar...

Challenges in Immuno-Oncology - Possibilities for Optimization.

Immuno-oncology has undoubtedly started a new era in the treatment of malignant diseases. Within a short time immunotherapeutic therapy concepts have become part of the standard therapy for many tumor...

Targeting the CD73-adenosine axis in immuno-oncology.

The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine. As such, they constitute critical components of the extracellular purine...

Demonstration of IgG Subclass (IgG1 and IgG3) in Immuno-Related Hemocytopenia.

Immuno-related hemocytopenia (IRH) is defined as idiopathic cytopenia of undetermined significance (ICUS) patients with autoantibodies. In our previous studies, we found that IgG1 levels were increase...

Clinical Trials [7345 Associated Clinical Trials listed on BioPortfolio]

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cel...

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patient...

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer ...

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Companies [1067 Associated Companies listed on BioPortfolio]

Immuno-Cell Int.

Immuno-Cell International © is specialized in the production of printed diagnostic slides and plates, for use in various types of diagnostic test kits. For the Diagnostic Industry (the manufactures o...


Manufacture of slides and cards for use in test kits.

NantCell, Inc.

NantCell, an entity controlled by Dr. Patrick Soon-Shiong, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by de...

MEDINET Co., Ltd. and MaxCyte, Inc.

MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technol...

Immuno Diagnostic Oy

Immuno Diagnostic Oy was established in 1983. Thus, we have a long experience in importing and marketing high quality reagents for diagnostics and research. We provide our customers with a wide range ...

More Information about "Immuno-Cell Int." on BioPortfolio

We have published hundreds of Immuno-Cell Int. news stories on BioPortfolio along with dozens of Immuno-Cell Int. Clinical Trials and PubMed Articles about Immuno-Cell Int. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immuno-Cell Int. Companies in our database. You can also find out about relevant Immuno-Cell Int. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record